Home

Sun Pharma Advanced Research Company Ltd PB Ratio

Image

Sun Pharma Advanced Research Company Ltd

NSE: SPARC

PB

52.8

Last updated on: 22 Nov 24

Key Highlights

  • The latest PB Ratio of Sun Pharma Advanced Research Company Ltd is 52.8.
  • The PB ratio of the Sun Pharma Advanced Research Company Ltd is above 3 which indicates that the stock is overvalued but this is common in high-growing sectors.
  • The P/B Ratio of Sun Pharma Advanced Research Company Ltd changed from 11.4 on March 2023 to 95.3 on March 2024 . This represents a CAGR of 189.13% over 2 years.

Historical P/B Ratio of Sun Pharma Advanced Research Company Ltd

No data available

Company Fundamentals for Sun Pharma Advanced Research Company Ltd

Market Cap

6,633 Cr

EPS

0.0

P/E Ratio (TTM)

0.0

P/B Ratio (TTM)

52.8

Day’s High

209.75

Day’s Low

190.45

DTE

0.5

ROE

-307.9

52 Week High

474.0

52 Week Low

189.45

ROCE

-130.8

Market Price of Sun Pharma Advanced Research Company Ltd

1M

1Y

3Y

5Y

Monitoring Sun Pharma Advanced Research Company Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 2024204.4
21 Nov 2024190.4
19 Nov 2024196.1
18 Nov 2024194.4
14 Nov 2024197.2

SWOT Analysis Of Sun Pharma Advanced Research Company Ltd

Strength

1

che

Weakness

2

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Sun Pharma Advanced Research Company Ltd

Asset Value vs Market Value of Sun Pharma Advanced Research Company Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/B Ratio

Company
leftPBright
Sun Pharma Advanced Research Company Ltd52.75
Sun Pharmaceuticals Industries Ltd99.4
Divis Laboratories Ltd515.7
Cipla Ltd365.8
Torrent Pharmaceuticals Ltd227.1

Historical Market Cap of Sun Pharma Advanced Research Company Ltd

Market Cap

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Sun Pharma Advanced Research Company Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

FAQs for PB Ratio of Sun Pharma Advanced Research Company Ltd

What is the PB ratio of Sun Pharma Advanced Research Company Ltd?

The current PB ratio of Sun Pharma Advanced Research Company Ltd is 52.75. The Price-to-Book value (P/B) ratio compares a company's current share price to its book value per share. It helps assess whether a stock is overvalued or undervalued relative to its net asset value.

What is the ideal PB ratio to buy Sun Pharma Advanced Research Company Ltd stocks?

An ideal PB ratio varies by industry; however, a PB ratio below 1.0 may indicate a good buying opportunity for Sun Pharma Advanced Research Company Ltd. Some investors and financial analysts may also consider any value under 3.0 as a good PB ratio.

How is the PB Ratio of Sun Pharma Advanced Research Company Ltd calculated?

The PB ratio of Sun Pharma Advanced Research Company Ltd is calculated by dividing the current share price by the book value per share. The book value per share is determined by dividing the company’s total net assets (assets minus liabilities) by the number of outstanding shares. This ratio helps evaluate how the market values the company's assets.

What does a high PB Ratio mean for Sun Pharma Advanced Research Company Ltd?

A high PB ratio suggests that Sun Pharma Advanced Research Company Ltd’s stock may be overvalued relative to its book value or that investors expect high growth.

What does a low PB Ratio indicate for Sun Pharma Advanced Research Company Ltd?

A low PB ratio of Sun Pharma Advanced Research Company Ltd may indicate that the stock is undervalued or it is facing financial difficulties.

Can Sun Pharma Advanced Research Company Ltd PB Ratio change over time?

Yes, the PB ratio of Sun Pharma Advanced Research Company Ltd can change over time due to fluctuations in the company’s stock price and changes in its book value.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*